Pharma Deals Review, Vol 2003, No 33 (2003)

Font Size:  Small  Medium  Large

Watson Pharmaceuticals Enters Agreement for Novartis’ Headache Treatments

Business Review Editor

Abstract


Watson Pharmaceuticals agreed to acquire US rights to two product lines Fioricet® and Fiorinal® for tension headaches, from Novartis Pharmaceuticals. The deal could worth up to US$178 M.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.